Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1611068

registered interest
date	17/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the accessibility of (1) medicines, and (2) clinical interventions, for secondary metastatic breast cancer in England.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL7158
answer	answer is ministerial correction date of answer 02/05/2023 answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP). For example, average times taken between licensing and the publication of NICE guidance for new medicines have been reduced from 10.2 months for 2017/18 to 3.1 months for 2022/23. The proportion of positive NICE recommendations increased from 79% in 2017/18 to 92% in 2022/23.</p><p>NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab deruxtecan and palbociclib, while allowing for the collection of further data on their clinical and cost effectiveness to inform a final NICE recommendation.</p><p>NICE published a surveillance review of its guideline on advanced breast cancer in January 2023. It concluded that the recommendations on biological therapy, chemotherapy, psychological support and preventing and managing complications will be updated. These updates will be scheduled into NICE’s work programme and will include equality impact assessments and consultation with stakeholders to ensure access issues are fully considered.</p><p>The NHS Cancer Programme has commissioned five new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 with the first outcomes expected in 2023/24. One of the five audits will cover primary and metastatic breast cancer.</p><p>The Department has not had specific discussions with the Devolved Governments. However, the Welsh Government and the Northern Ireland Department of Health have agreements in place with NICE to use their technology appraisals and clinical guidelines. NICE will engage with them to support implementation. Both NICE and the Scottish Medicines Consortium are permanent partners in ILAP. Decisions on how guidance is implemented is a matter for each Government.</p> answering member printed Lord Markham grouped question UIN HL7159 question first answered 02/05/2023 16:08:20 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1611069

registered interest
date	17/04/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with the devolved administrations regarding the accessibility of (1) medicines, and (2) clinical interventions, for secondary metastatic breast cancer.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL7159
answer	answer is ministerial correction date of answer 02/05/2023 answer text <p>The Government is committed to supporting timely patient access to clinically- and cost-effective new drugs, including for metastatic breast cancer. The Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE) and NHS England are working closely together to ensure that there is a joined-up, timely approach to supporting access to new medicines for National Health Service patients, including those licensed through Project Orbis and the creation of the Innovative Licensing and Access Pathway (ILAP). For example, average times taken between licensing and the publication of NICE guidance for new medicines have been reduced from 10.2 months for 2017/18 to 3.1 months for 2022/23. The proportion of positive NICE recommendations increased from 79% in 2017/18 to 92% in 2022/23.</p><p>NICE is also able to make recommendations through the cancer drugs fund (CDF), which has benefitted over 88,000 patients as of March 2023. The CDF has allowed patients with metastatic breast cancer to access new medicines like trastuzumab deruxtecan and palbociclib, while allowing for the collection of further data on their clinical and cost effectiveness to inform a final NICE recommendation.</p><p>NICE published a surveillance review of its guideline on advanced breast cancer in January 2023. It concluded that the recommendations on biological therapy, chemotherapy, psychological support and preventing and managing complications will be updated. These updates will be scheduled into NICE’s work programme and will include equality impact assessments and consultation with stakeholders to ensure access issues are fully considered.</p><p>The NHS Cancer Programme has commissioned five new cancer clinical audits, which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatment and outcomes for patients. The Royal College of Surgeons began work on this audit in October 2022 with the first outcomes expected in 2023/24. One of the five audits will cover primary and metastatic breast cancer.</p><p>The Department has not had specific discussions with the Devolved Governments. However, the Welsh Government and the Northern Ireland Department of Health have agreements in place with NICE to use their technology appraisals and clinical guidelines. NICE will engage with them to support implementation. Both NICE and the Scottish Medicines Consortium are permanent partners in ILAP. Decisions on how guidance is implemented is a matter for each Government.</p> answering member printed Lord Markham grouped question UIN HL7158 question first answered 02/05/2023 16:08:20 answering member 4948 label Biography information for Lord Markham
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1605049

registered interest
date	16/03/2023
answering body	Department for Levelling Up, Housing and Communities
answering dept id	211
answering dept short name	Levelling Up, Housing and Communities
answering dept sort name	Levelling Up, Housing and Communities
hansard heading	UK Shared Prosperity Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the termination of the European Social Fund on 31 March, when funding will be made available from the UK Shared Prosperity Fund to social economy projects throughout the UK.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6580
answer	answer is ministerial correction date of answer 29/03/2023 answer text <p>The economic inactivity competition closed on 27 January 2023, and we received a strong and positive response from organisations across Northern Ireland seeking to deliver economic inactivity and Multiply support. Project assessment has now concluded and we are working with a view to taking final selection decisions as quickly as possible.</p><p>We recognise the need for this important funding to be in place promptly as the European Social Fund support draws to a close in Northern Ireland at the end of this month.</p><p> </p><p> </p> answering member printed Baroness Scott of Bybrook question first answered 29/03/2023 16:32:16 answering member 4553 label Biography information for Baroness Scott of Bybrook
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1604688

registered interest
date	15/03/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Horizon Europe
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government why Horizon Europe is not part of their Science and Technology Framework, published on 6 March.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6536
answer	answer is ministerial correction date of answer 29/03/2023 answer text <p>I refer the noble Baroness to the answer given by my Hon. Friend the Minister of State for Science, Research and Innovation to the Hon Member for Newcastle upon Tyne Central on 14th March 2023 to Question 158905.</p> answering member printed Viscount Camrose question first answered 29/03/2023 14:54:25 answering member 4939 label Biography information for Viscount Camrose attachment 1 file name UIN 158905.pdf title Answer to Question 158905
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1604689

registered interest
date	15/03/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Horizon Europe: Marine Environment
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what discussions they have had with the marine science community about the future of the UK’s involvement in Horizon Europe.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6537
answer	answer is ministerial correction date of answer 29/03/2023 answer text <p>The Government continues to be ready to work constructively with the EU on a range of issues including UK association to Horizon Europe.</p><p> </p><p>The Department has socialised plans on alternatives to Horizon with the marine science sector in June and December 2022 roundtables during their development. We will continue to put the interests of businesses and researchers across the UK, including in the marine science community, first so they can take forward ground-breaking research and drive forward innovation with their international partners.</p> answering member printed Viscount Camrose question first answered 29/03/2023 14:53:53 answering member 4939 label Biography information for Viscount Camrose
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1604690

registered interest
date	15/03/2023
answering body	Department for Energy Security and Net Zero
answering dept id	215
answering dept short name	Energy Security and Net Zero
answering dept sort name	Energy Security and Net Zero
hansard heading	Carbon Emissions
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what consideration they have given to including provisions on carbon leakage as part of the Energy Bill.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6538
answer	answer is ministerial correction date of answer 29/03/2023 answer text <p>The Government is delivering the landmark Energy Bill which will liberate private investment in clean technologies and deliver the crucial transformation of the energy system for the long term.</p><p> </p><p>The UK recognises the importance of addressing the risk of carbon leakage to ensure that its ambitious policy of decarbonisation is not undermined through the transition to Net Zero.</p><p> </p><p>Whilst the Energy Bill does not contain explicit provisions relating to carbon leakage, the Government committed to consult on a range of potential mitigations for carbon leakage in the spring.</p> answering member printed Lord Callanan question first answered 29/03/2023 15:33:22 answering member 4336 label Biography information for Lord Callanan
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1604691

registered interest
date	15/03/2023
answering body	Department for Energy Security and Net Zero
answering dept id	215
answering dept short name	Energy Security and Net Zero
answering dept sort name	Energy Security and Net Zero
hansard heading	Carbon Capture and Storage
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what environmental monitoring will form part of future carbon capture and storage projects beneath the seabed.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6539
answer	answer is ministerial correction date of answer 29/03/2023 answer text <p>Upon receiving an application for a carbon dioxide storage permit, the North Sea Transition Authority (NSTA) is required by law to ensure (amongst other requirements) that the storage complex and surrounding area have been sufficiently characterised and assessed to ensure there is no significant risk of leakage, or of harm to the environment or human health. As part of the storage permit application, the operator will be required to set out a monitoring plan to demonstrate conformance and containment, detection, and measurement of a significant irregularity or leakage event.</p> answering member printed Lord Callanan question first answered 29/03/2023 16:09:52 answering member 4336 label Biography information for Lord Callanan
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1604692

registered interest
date	15/03/2023
answering body	Department for Science, Innovation and Technology
answering dept id	216
answering dept short name	Science, Innovation and Technology
answering dept sort name	Science, Innovation and Technology
hansard heading	Horizon Europe
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government when they expect that negotiations will be completed with the EU regarding (1) membership of, and (2) access to, Horizon Europe.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6540
answer	answer is ministerial correction date of answer 29/03/2023 answer text <p>Following the agreement of the Windsor Framework, the Government welcomes the EU’s openness to discussions following two years of delays. The Government continues to be ready to work constructively with the EU on a range of issues including UK association to Horizon Europe. The EU have not yet made any proposals to address the financial terms of UK association, given we are now over 2 years into a 7-year programme.</p><p> </p><p>The Government has acted to support researchers and businesses across the UK by introducing the Horizon Guarantee - now extended until end June 2023 and, in November last year, announced £684m of investment into UK R&amp;D.</p> answering member printed Viscount Camrose question first answered 29/03/2023 14:52:10 answering member 4939 label Biography information for Viscount Camrose
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

1604693

registered interest
date	15/03/2023
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Disease Control: International Cooperation
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the impact of the Financial Intermediary Fund for Pandemic Prevention, Preparedness and Response on tackling (1) new diseases, and (2) existing diseases such as malaria.
tabling member printed	Baroness Ritchie of Downpatrick
uin	HL6541
answer	answer is ministerial correction date of answer 28/03/2023 answer text <p>The UK is shaping discussions to improve pandemic prevention, preparedness and response globally. In June 2022, the UK announced a £25 million commitment to the Pandemic Fund. The Fund should fill some of the financing gaps for preparedness in health systems and disease surveillance at country, regional and global levels including by catalysing countries' own financing so that they are better prepared to detect and respond whenever and wherever a health risk emerges. Improved health systems preparedness and surveillance should positively impact wider disease control efforts, including new diseases and malaria.</p> answering member printed Lord Goldsmith of Richmond Park question first answered 28/03/2023 16:18:22 answering member 4062 label Biography information for Lord Goldsmith of Richmond Park
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick